CTLA4 and neoplasm: The ADCC mediated by TAMs was shown in a study where melanoma patients responders to ipilimumab (mAb anti-CTLA-4) had higher numbers of circulating CD16+ monocytes and macrophages at tumor sites and lower Treg cells (225).